Empagliflozin impurities include process-related compounds, degradation products, and structurally related analogs formed during synthesis or storage. These are monitored to ensure the safety and efficacy of this sodium-glucose co-transporter-2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus. All materials are structurally confirmed and qualified under ICH guidelines for pharmaceutical analysis and toxicological evaluation.
We offer pharmacopeial and non-pharmacopeial Empagliflozin impurities that comply with European Pharmacopoeia (EP) specifications. These impurity standards are essential for method development, impurity profiling, and stability testing. Analytical techniques such as HPLC, LC-MS, and NMR are used for their identification and quantification. EP traceable standards are available upon request.
Our catalog includes Empagliflozin-related compounds such as synthetic intermediates and degradation products. These entries are used in forced degradation studies, impurity identification, and genotoxicity screening. All materials are thoroughly characterized and supported by detailed analytical documentation.
Empagliflozin impurity reference standards are supplied with validated analytical data including NMR, MS, and HPLC purity. These materials are used in pharmaceutical R&D, ANDA and DMF filings, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request, and all products meet international regulatory expectations. Supplied materials are re-tested at regular intervals to ensure consistency.
Register to add the product to RFQ list
Already have an account? Log in here
Don’t have an account? Register here
